Join us on June 24 at 4:00 pm US ET for this special webinar on the findings from Fulcrum Therapeutics’ ReDUX4 clinical trial. The Fulcrum team will be sharing the data from its Phase 2b clinical trial of Losmapimod, a treatment for FSH muscular dystrophy that is intended to stop the expression of the DUX4 gene and slow the progression of symptoms. The data will be publicly presented for the first time earlier on June 24 at the FSHD Society’s International Research Congress. This webinar will be the first presentation of the data to patients and families. There will be time for Q&A. Register to attend by clicking on the link below.